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Aims: Drug regulators issue safety advisories to warn clinicians and the public about new 
evidence of harmful effects of medicines. It is unclear how often these messages are covered 
by the media. Our aim was to analyse the extent of media coverage of two medicines that 
were subject to safety advisories from 2007 to 2016 in Australia, Canada, United Kingdom 
and United States.  
 
Methods: Two widely-used medicines to treat mental health or physical conditions were 
selected: citalopram and denosumab. Media reports were identified by searching LexisNexis 
and Factiva. Reports were included if they stated at least one health benefit or harm. A 
content analysis of the reports was conducted.  
 
Results: In total, 195 media reports on citalopram and 239 on denosumab were included. For 
citalopram, 43.1% (84/195) of the reports mentioned benefits, 85.6% (167/195) mentioned 
harms and 9.7% (19/195) mentioned the harm described in the advisories (cardiac 
arrhythmia). For denosumab, 94.1% (225/239) of the reports mentioned benefits and 39.7% 
(95/239) mentioned harms. The harms described in the advisories were rarely mentioned: 
10.9% (26/239) of the reports mentioned osteonecrosis and ≤5% mentioned any of the other 
harms (atypical fractures, hypocalcemia, serious infections, and dermatologic reactions).  
 
Conclusions: We found limited media coverage of the harms highlighted in safety advisories. 
Almost two-thirds of the media stories on denosumab did not include any information about 
harms, despite the many advisories during this time frame. Citalopram coverage covered 
harms more often but rarely mentioned cardiac arrhythmias. These findings raise questions 
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What is already known about this subject:  
 
 Drug regulators issue safety advisories to warn about emergent risks of medicines. 
The effectiveness of these warnings can vary, with one key determinant whether they 
reach the intended audience. 
 
 Media reports could influence awareness of harms reported in safety advisories and 
subsequent shifts in health care utilisation. However, it is unclear how often drug 
regulators’ messages on safety concerns of medicines are transmitted through media 
coverage. 
 
 Previous research has shown significant shortcomings in media coverage of 
medicines, including overstating of benefits and downplaying of harms.  
 
 
What this study adds: 
 
 There was limited media coverage of the safety concerns highlighted in advisories 
released by drug regulators on citalopram and denosumab. 
 
 While citalopram coverage often covered harms, almost two-thirds of the media 
stories on denosumab did not include any information about harms, despite the many 
advisories released during this time frame.  
 
 The media can be an important conduit for medicine safety communication and its 
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Background  
 
Drug regulatory agencies regularly issue safety advisories to warn clinicians and the public 
about new evidence of harmful effects of medicines, with the aim of guiding safer prescribing 
and use. The effectiveness of these warnings can vary, and one key determinant of this is 
whether they reach the intended audience.[1] 
 
The general media is an important channel for public health communication and for raising 
awareness about threats to human health.[2] This avenue may be particularly important when 
drug safety concerns emerge. For example, in the early 1980s the media were an important 
channel for the diffusion of information about the relationship between use of aspirin and 
Reye’s syndrome.[3] Media coverage coincided with a sudden decline in Reye’s syndrome 
incidence in the United States.[3] Similarly, in 2002-2003 a decline in hormone replacement 
therapy use was observed following the extensive media coverage generated by the 
publication of the Women’s Health Initiative, a trial that demonstrated the risks of hormone 
therapy.[4] 
 
Due to their potential to affect clinical practice and health care utilisation, media reports 
could also influence uptake of safety advisories. However, it is unclear how often regulators’ 
drug safety messages are transmitted through media coverage around the time that the 
advisory is disseminated. Previous research has shown significant shortcomings in media 
coverage of medicines, including overstating of benefits and downplaying of harms.[5, 6] For 
example, an analysis of Canadian newspaper coverage about five prescription medicines 
found that beneficial effects were mentioned 4.7 times more often than harms.[5] Concerns 
have also been raised about the failure to include information on funding sources and 
financial ties of investigators when scientific research is reported in the media.[6, 7] 
 
The objective of this study was to analyse the extent and patterns of media coverage of two 
medicines that were subject to safety advisories in four countries -Australia, Canada, United 
Kingdom (UK) and United States (US). A secondary objective was to assess whether funding 
source and financial ties of investigators of the scientific studies cited in the media were 
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Methods 
 
We used a case study approach in order to conduct an in-depth exploration of media coverage 
of safety advisories.[8] We intentionally chose as illustrative case studies two different types 
of medicines used by different subsets of patients under different circumstances. The four 
countries were selected for their similar medical traditions, population size and demographics 
(Australia and Canada), for their strong influence on drug regulation internationally (UK and 
US), and for the possibility to analyse media reports without need for translation.  
 
Identification of the case studies 
Our team previously compiled all of the post-market safety advisories issued by drug 
regulatory agencies in Australia, Canada, UK and US from 01 January 2007 to 31 December 
2016.[9] Safety advisories were defined as communications to prescribers and/or the public 
about real or potential safety concerns intrinsic to the medicines’ effects. We excluded 
communications about manufacturing problems, drug shortages, misuse and overdose. Over 
this 10-year period, 1441 advisories were identified in the four countries after excluding 
duplicate advisories by the same regulator and on the same medicine and safety issue within a 
30 day period. Based on discussion among co-investigators, we selected two widely-used 
medicines using the following criteria: 
 medicines that may be prescribed by general practitioners as well as specialists;  
 one medicine used to treat mental health conditions and one medicine used to treat 
physical conditions; 
 medicines that were subject to serious safety concerns and for which at least one of 
the four regulators had issued an alert or a Direct Healthcare Professional 
Communication (DHPC) as these are the main communication interventions used by 
drug regulators to deliver important information directly to healthcare 
professionals.[10, 11] However, it should be noted that in Australia DHPCs are not 
publicly available,[12] therefore our list of Australian safety advisories could be 
incomplete. 
Based on these criteria, we selected citalopram, an antidepressant of the selective serotonin 
reuptake inhibitor (SSRI) class, and denosumab, a monoclonal antibody that inhibits the 
activity of osteoclasts. Denosumab is frequently used for the treatment of osteoporosis, but a 
higher dose formulation is also used to prevent complications caused by bone malignancies 
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and to treat giant cell tumor of the bone.[13] The final decision about which medicines to 
include was made before analysing any media coverage. Table 1 lists the safety concerns 
highlighted in the advisories that were issued on citalopram and denosumab during the study 
period. Citalopram was subject to advisories on risks of QT prolongation and cardiac 
arrhythmia, and denosumab was the focus of advisories on the risks of atypical fractures, 
hypocalcemia, osteonecrosis, serious infections, and dermatologic reactions. 
 
Database search 
We identified English-language media coverage in Australia, Canada, UK and US by 
searching Lexis Nexis and Factiva, two electronic databases of global news. In order to assess 
whether there was an increase in media reporting after advisories, we identified media reports 
about citalopram and denosumab from one year before the first advisory to one year after the 
last advisory in any included country. Searches were carried out using the generic and the 
originator brand names of citalopram and denosumab in Australia, Canada, UK and US 
(Citalopram search: citalopram OR escitalopram OR cipramil OR celexa OR lexapro OR  
cipralex; Denosumab search: denosumab OR Xgeva OR Prolia). We included general media 
such as print and online journalism (daily, weekly and monthly newspapers and magazines, 
news blogs, radio/television journalism). Broadcast transcripts were also included from 
Factiva, but not from Lexis Nexis where most broadcast transcripts were ‘unclassified’ with 
regard to the geographical provenance.  
 
 
Eligibility criteria  
Two investigators independently screened the full texts of all the retrieved media reports for 
inclusion, applying the following criteria: 
 at least one health benefit or harm (including a lack of effect) of the selected medicines 
was stated. This could have been any health outcome. We included reports on non-
approved as well as approved indications, and reports about claims of cost-effectiveness; 
 the media report was from Australia, Canada, UK or US. 
We excluded the following types of media reports: 
 those only mentioning the drug indication without any other information on beneficial or 
harmful effects, for example “citalopram is a treatment for depression”; 
 those only mentioning market share, profitability, and other business issues; 
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 press releases (these were excluded because their intended audience is media outlets and 
journalists, and we were only interested in the final media reports that are read by the 
public); 
 reports in the medical press (journals with a health professional audience).  
Discrepancies between coders on inclusion/exclusion were resolved by consensus. If 
agreement could not be reached, a third assessor adjudicated. Media reports were often 
syndicated and made available via multiple news outlets. For the included media reports, we 
kept track of the number of syndicated reports but coded only the first one which appeared. 
 
Data collection  
We conducted a content analysis of the identified media reports examining: 
 the type of benefits and harms mentioned; 
 whether the harms listed in the advisories were mentioned and whether the media 
report portrayed an increased risk of harm or minimised the risk of harm (e.g. stating 
that no cases were found or that the cases were not serious); 
 who was cited;  
 whether identifiable research studies (primary empirical research and systematic 
reviews, but not editorial or opinion pieces) were cited, and if so, whether funding 
source and financial ties of investigators were reported; 
 the coders’ assessment of the overall emphasis of the media reports (mainly on harms 
of the medicine, mainly on benefits, neutral, unclear).  
 
We created a structured coding questionnaire to assess the above (see Supplementary File 1) 
that was pilot tested with 25 media reports in order to address ambiguities identified through 
coding disagreements. A written manual with instructions was developed and a training 
session for the coders was conducted before starting the data collection. From each included 
record, four assessors (working in pairs) independently extracted the above mentioned 
information using Redcap, a secure web-based application for data collection and 
management.[14] Discrepancies in data extraction were resolved by consensus. If agreement 
could not be reached, a third assessor adjudicated. 
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For the media reports mentioning the safety concerns described in the advisories, we also 
conducted an additional analysis looking at the type of news source (e.g. newspaper, 
magazine, blogs) and coverage (e.g. local or national). 
Concordance between reporting of financial ties in media reports and related scientific 
articles 
If specific scientific studies were reported in news articles, we determined whether 
information on funding source and investigators’ financial conflicts of interest was available 
to journalists from the published study report. We recorded the study name, author, journal, 
and date (when available). We then searched PubMed and Google for the scientific journal 
articles that were mentioned in the media reports. Two investigators independently examined 
these articles for research funding and authors’ financial conflict of interest disclosures. We 
then compared this information with the disclosures in the media.  
 
Statistical analysis 
We graphed monthly media coverage counts for the entire study period. Descriptive statistics 





In total, 3452 media reports were screened, 1603 on citalopram/escitalopram and 1849 on 




In total, 195 articles on citalopram/escitalopram were included. (Figure 1) As Table 2 shows, 
5.1% of the reports (10/195) mentioned the brand name in the title and 65.6% (128/195) 
specified the treatment indication. In total, 13.8% (27/195) only mentioned benefits, 28.7% 
(56/195) cited both benefits and harms, and 56.9% (11/195) only mentioned harms. The harm 
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The overall emphasis of 69.7% (136/195) media reports was found to be mainly on harms of 
citalopram, and 20.0% (39/195) on benefits. The emphasis was found to be unclear in 8.2% 
(16/195) of reports and neutral (presenting both benefits and harms equally) in 2.1% (4/195) 
of reports.  
 
Reporting benefits and harms 
Among media reports mentioning benefits, these most frequently related to improvements in 
depression (16.4%, 32/195) or anxiety (7.2%, 14/195), or general statements about 
effectiveness (6.7%, 13/195). In 12.8% (25/195) of the reports the benefits were described 
through the positive experience of a patient with statements such as “it was miraculous”, “it 
was brilliant”, “after about six weeks I was just back to myself”. Benefits were quantified in 
8.2% (16/195) of the reports.   
 
The number of media reports per month before and after the release of the safety advisories 
are shown in Figures 3 and 4 for citalopram, and citalopram and cardiac arrhythmias 
respectively. All media reports including information on cardiac arrhythmia (9.7%, 19/195) 
were published after the first safety advisory and portrayed an increased risk of harm with 
statements such as: 
 "Health Canada says consumers should avoid taking a daily dose of the 
antidepressant Celexa in excess of 40 milligrams. The drug's Canadian distributor, 
Lundbeck Canada, says doses higher than that can cause abnormal heart rhythms." 
[15]  
 "In Britain, meanwhile, doctors have been told to lower the maximum dose of the 
UK's most widely prescribed antidepressant, Cipramil, after a study last month 
revealed that the drugs increase the risk of heart problems which can cause sudden 
death". [16] 
There was an increase in citalopram coverage when the first US advisory was published in 
August 2011. Out of the 21 US media reports on citalopram published that month, six 
focused on cardiac arrhythmia. The second US advisory in March 2012 received less 
coverage. The Canadian advisories released in October 2011 and January 2012 were both 
covered in three media reports, and there was no coverage of the advisory released in May 
2012. An additional Canadian media report was published in February 2013, prompted by a 
new study on cardiac risks of antidepressants. In the UK we identified three media reports on 
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the cardiac risks of citalopram. They were published several months after the release of the 
advisories by the Medicines and Healthcare products Regulatory Agency and were prompted 
by new scientific studies. As Table 3 shows, most of the media outlets mentioning cardiac 
arrhythmia were press services with national coverage (12/19).  
 
Other safety concerns were described in 77.9% (152/195) media reports.(Table 2) The most 
frequently reported adverse effects were: suicidal thoughts or behaviours (19.5%, 38/195), 
homicidal thoughts and violence (17.9%, 35/195, of which 27 were related to homicide 
trials), withdrawal symptoms (10.8%, 21/195), lack of effectiveness in treating depression 
(9.2%, 18/195) and sexual side effects (8.7%, 17/195).  
The top three types of people cited in the media reports were scientists/academics (31.8%, 
62/197) followed by patient/consumers (29.7%, 58/195) and legal professionals or coroners 
(24.1%, 47/195).  
 
Reporting funding source and conflicts of interest 
Specific studies on citalopram/escitalopram or the SSRI class were cited in 31% (60/195) of 
media reports and in less than half of these (n=28) sufficient information was included to 
identify the published study. Some studies were reported in multiple media stories; in total 
we identified 21 published scientific articles that were mentioned 36 times in the 28 media 
reports. As Table 4 shows, while information on funding source and investigators’ conflicts 
of interest was readily available in the scientific articles, there was little reporting of this 
information in media reports.  
 
Denosumab 
In total, 239 reports on denosumab were included.(Figure 2) As Table 5 shows, 41.8% of the 
reports (100/239) mentioned the brand name in the title and 96.2% (230/239) specified the 
treatment indication. In total, 60.3% (144/239) only mentioned benefits, 34.0% (81/239) 
stated both benefits and harms, and 5.9% (14/239) only mentioned harms. The harms 
mentioned in the advisories were rarely reported.  
 
Accordingly, the overall emphasis of 81.6% (195/239) of the media reports was considered to 
be mainly on benefits of denosumab, 12.6% (30/239) mainly on harms, in 3.3% (8/239) the 
emphasis was neutral (namely, presenting both benefits and harms equally), and 2.5% (6/239) 
were unclear.  
 
This article is protected by copyright. All rights reserved. 
Reporting benefits and harms 
Figure 5 shows the number of media reports on denosumab per month. There was a surge in 
media coverage in 2011 and 2012, especially in the US where the majority of the reports 
were related to the publication of results of clinical trials, and to successes or failures in 
getting regulatory approval for new indications. 
 
Among the media reports mentioning benefits, the most frequent reported effects were 
prevention or delay of bone metastases (36.8%, 88/239), benefits for osteoporosis (e.g. 
increase bone mass) (29.3%, 70/239), and a potential new use of denosumab for prevention 
of breast cancer (9.2, 22/239). Benefits were quantified in 26.4% (63/239) of the reports.   
 
The harms mentioned in the advisories were infrequently reported (Figures 6-10): 
 The risk of atypical fracture was mentioned in 4.6% (11/239) of the media reports; nine 
reports portrayed an increased risk of atypical fractures, and two minimised the risk. 
Three reports were published in Canada immediately after the first advisory in November 
2012. None of the other articles were related in time to the advisories nor did they 
mention the advisory or drug regulators.  
 The risk of hypocalcemia was mentioned in 3.8% (9/239) of the media reports; seven of 
which stated that there was an increased risk of hypocalcemia, and two minimised the 
risk. Only two reports were stimulated by the release of a safety advisory in Australia in 
August 2016. Although safety advisories were also released in Canada, UK and US, there 
was no coverage of the advisories. 
 The risk of osteonecrosis was described in 10.9% (26/239) of the media reports; 23 
reports portrayed an increased risk, two minimised the risk and one was unclear. Most 
reports (n=19) were published before the first safety advisory in US and were related to 
the publication of preliminary results of clinical trials, and to successes or failures in 
getting marketing authorisation for new indications. None of the six advisories on 
osteonecrosis generated an increase in media coverage.  
 Only 1.7% (4/239) and 0.8% (2/239) of the media reports covered serious infections and 
dermatologic reactions, respectively. Based on the timing and content of these reports, 
none appeared to have been stimulated by the release of three safety advisories in the US. 
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Most of the articles mentioning the harms described in the advisories were published in 
media outlets with national coverage.(Table 3) As stated above, while some media reports 
stated that there was an increased risk of the harms mentioned in the advisories, other 
minimised the risk. Below we report two illustrative quotes from two articles that increased 
and minimised the risk of harm, respectively: 
 "...it can occasionally lead to osteonecrosis of the jaw and atypical fractures. 
And, for people with kidney disease, it can lead to drops in calcium levels that 
can cause muscle spasms and abnormal heart rhythms. Finally, because 
Prolia is injected into the skin and may affect immune function, it may slightly 
increase the risk of skin infections at the site of the injection.[17] 
 "Rates of adverse events, serious adverse events, and fatal adverse events 
were similar in the treatment groups, and there were no cases of 
hypocalcemia, jaw osteonecrosis, complications of fracture healing, or 
atypical femoral fractures during the study". [18] 
 
Other safety concerns were described in 31.8% (76/239) media reports. The most frequently 
reported were: unspecified side effects (13.4%, 32/239) and lack of effect such as failure to 
meet the study endpoint in a clinical trial (7.1, 17/239).  
The top three types of actors cited in the media reports were the drug industry (38.5%, 
92/239), followed by scientists/academics (20.9%, 50/239) and drug regulators (11.7%, 
28/239).  
 
Reporting funding source and conflicts of interest 
In 31 media reports sufficient information was provided to identify the specific published 
study that was cited. We identified 13 published scientific articles that were mentioned in 
these 31 reports. As Table 4 shows, while information on funding source and investigators’ 
conflicts of interest were usually readily available in the scientific articles, the reporting of 
this information in the media was very limited.  
Moreover, a higher proportion of research articles cited in media reports for denosumab 
(75.0%) were funded by industry compared with citalopram (10.5%). 
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Discussion 
In this study, we aimed to characterise media coverage of two medicines that were subject to 
serious safety concerns. We found limited media coverage of the safety concerns highlighted 
in advisories released by drug regulators. For citalopram, the risk of cardiac arrhythmia was 
mentioned only in 10% of the media reports. For denosumab, the risk of osteonecrosis was 
mentioned in just 11% of media reports, while the other safety concerns mentioned in the 
advisories were reported in ≤5% of the reports. Despite the limited media coverage in all four 
countries, in the citalopram case study we observed an interesting pattern in the US and 
Canada: the coverage of subsequent advisories tended to decline, in comparison with 
coverage after the initial advisory. ‘Media fatigue’ could explain this pattern as journalists 
may not be interested in covering the same issue again.[19] We did not find any association 
between the amount of media coverage and the type of communication used (e.g. safety alert, 
DHPC, bulletin article) but our ability to assess any differential effect by communication tool 
was limited by the small number of media reports per advisory. 
We found an asymmetry between citalopram and denosumab in the proportion of media 
coverage about harm compared to benefit. While most citalopram media coverage mentioned 
harms (86%), most of the media reports on denosumab cited benefits (94%) and almost two 
thirds of the stories did not mention a single potential harmful effect. For both medicines, 
most of the reports lacked quantitative information on benefits and harms that could help the 
readers to understand the likelihood of these effects. A possible explanation for the difference 
in media coverage of the two medicines is that antidepressants in general are an established 
and often controversial topic in the media. Previous analyses of Danish, Dutch and British 
newspapers have reported negative media coverage on antidepressants.[20, 21] Another 
possible explanation might be the “drug age”. While citalopram is an older and off-patent 
medicine that has been on the market for longer (e.g. since 1998 in US), denosumab is still 
on-patent [22] and a relatively recent medicine (e.g. on the market from 2010 in US) and this 
could have stimulated an overly enthusiastic media coverage. An overall positive bias in the 
presentation of information on new medicines was found in previous studies in Canada and 
US.[5, 6] Several hypotheses have been developed to explain this phenomenon such as 
journalists’ reliance on industry-sponsored materials [23] or on press releases about scientific 
research that have been found to often exaggerate the importance of findings.[24] 
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We also found that when making reference to scientific studies, only a few media reports 
mentioned the funding source and whether the study authors had any financial links to 
pharmaceutical companies, despite this information being readily available in most of the 
cited scientific articles. Evidence across several fields has shown that industry funding and 
authors’ conflicts of interest related to commercial companies can influence the research 
process.[25, 26] For example, examinations of pharmaceutical industry-sponsored research 
show that such funding produces studies with outcomes that are favourable to the sponsor 
more often compared with non industry-funded studies.[27] Public disclosure of research 
funding and authors’ conflicts of interest is now routinely required by medical journals [28] 
and we urge journalists to incorporate this information to allow the readers to critically assess 
the reported research.  
Interestingly, in both case studies, we found that scientists and academics were among the 
most cited actors in the media reports while regulators were less frequently cited or 
mentioned. This suggests that journalists value academic researchers as an information source 
and may be interviewing researchers in order to convey the relevant research evidence. We 
did not measure whether the cited researchers accurately conveyed the research evidence. 
However, the infrequent quantification of either benefit or harm and the many articles 
mentioning only benefits or only harms suggests a need for improvement. Contacts between 
journalists and experts have been described as a “meeting between two professional cultures” 
and calls have been made to improve the communication skills of both sectors in order to 
improve the quality of the interaction and of the outcome.[29] 
Our study has some limitations. First, the patterns seen with these two illustrative cases may 
not reflect those seen with other medications. Similarly, the trends in the four included 
countries may differ from those in other countries or other time periods. Second, we excluded 
press releases because we were interested only in the final media reports that are read by the 
public. Third, although we excluded media reports that did not have any mention of 
beneficial or harmful effects of the drugs, we did not control for the overall focus of the 
reports. For example, in media reports where the health effects of the drug were only 
mentioned in passing, some information might have been appropriately omitted. Fourth, we 
did not examine the accuracy of the claims about the included drugs as this was beyond the 
scope of our study. Finally, the analysis of funding and conflict of interest disclosures was 
conducted only for the subset of media reports that provided sufficient information to identify 
 
This article is protected by copyright. All rights reserved. 
the published scientific study.  
 
This study builds on previous work looking at media and pharmacovigilance. For example, 
Woloshin et al. analysed the amount and content of media coverage of safety advisories on 
zolpidem released by the Food and Drug Administration and found high variability, with only 
some messages broadly reported.[19] The media play an important role in communicating 
about medicine safety issues and their role in extending the reach of drug regulators’ 
messaging could be improved. Unfortunately our data does not allow us to explain why these 
important messages were not broadly picked up by the media and we do not know to what 
extent regulators deliberately target media channels to help communicate safety messages. 
Careful consideration needs to be given to the duration and amount of media coverage that 
may be of most benefit to the public. Whilst media coverage tends to be short-lived, 
information on medicine safety needs to be consistently available to the public.[30] Medicine 
regulators may therefore need to consider a multi-faceted strategy to disseminate 
pharmacovigilance messages to the public, taking advantage also of the increasing use of 
social media.  
 
Journalists clearly face challenges in producing good quality media reports due to lack of 
time, and pressure to write stories that are concise as well as interesting.[29] Although it 
would be impractical for journalists to cover every potential beneficial and harmful effect, 
media reports should allow readers to develop a balanced assessment of medicines and health 
interventions. In this regard, there have been several calls and attempts to improve the quality 





We found limited media coverage of the safety concerns highlighted in advisories released by 
drug regulators. Almost two-thirds of the media stories on denosumab did not include any 
information about harms, despite the many advisories relating to five different safety 
concerns during this time frame. Citalopram coverage covered harm more often, but rarely 
mentioned cardiac arrhythmias, the subject of the safety advisories. These findings raise 
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questions about how to better ensure that regulatory risk communications reach the general 
public, including users of the medicine in question, so that they are able to make informed 
decisions. Outcomes from these case studies should be compared with media uptake of other 
regulators’ messages to help regulators expand dissemination of these important messages to 
the public and ensure the greatest public health impact. 
Our findings also raise concerns about the quality and completeness of media coverage of 
medicines. Many media reports included an unbalanced reporting of expected benefits and 
potential harms of drug use; drug effects were also rarely quantified. Given their potential to 
affect clinical practice and health care utilisation, media should allow readers to develop a 
balanced assessment of medicines and health interventions so that they can make informed 
decisions.[5] Finally when media reports referred to specific scientific studies, reporting of 
funding source and conflicts of interest was limited. We urge journalists to more regularly 
report this information in order to allow the readers to critically assess the reported 
research.[7] 
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Table 1. Safety advisories released on citalopram and denosumab within the study 
period 
Safety concerns Safety advisories (country, month/year, and category of safety 
advisories)a 





02/12 Bulletin 10/11  Investig. 10/11  DHPC 08/11  Alert 
01/12 DHPC 12/11 DHPC 03/12 Alert 
05/12 Alert 
Denosumabb 





06/14  REMS 
02/15 REMS 
05/15 REMS 
Hypocalcemia 04/13  Bulletin 05/12 DHPC 09/12  DHPC 06/14  REMS 
08/16 Bulletin 10/12 Alert 02/15 REMS 
08/14 DHPC 05/15 REMS 
Osteonecrosis  
 
04/16 Bulletin  08/14 DHPC 06/14  REMS 
06/15 DHPC 02/15 REMS 
05/15 REMS 





   06/14  REMS 
02/15 REMS 
05/15 REMS 
a) Categories of safety advisories: Direct Healthcare Professional Communication (DHPC), 
Alert, Investigation, Bulletin Article, Public Communication, Risk Evaluation and 
Mitigation Strategy (REMS). 
b) Also neoplasm, hearing loss, cardiovascular disorders – Canadian Summary Safety 
reviews with no findings of risk/not enough evidence to suggest an association.   
c) In April 2013 the Therapeutic Goods Administration (TGA) published an article on 
“Denosumab and severe hypocalcemia” in the Medicines Safety Update, the medicines 
safety bulletin of the TGA. The article briefly mentioned that the Product information 
“was also updated to specify that atypical femoral fractures have been reported in 
patients being treated with Prolia”. 
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Table 2. Characteristics of the media reports on citalopram 
 n (%) 
Media reports 195 (100) 
Brand name in the headline 10 (5.1) 
Treatment indication specified 128 (65.6) 
Any benefit mentioned 
Type of benefita 
 Improve depression 
 Improve anxiety 
 Effective 
 Reduce hot flashes 
 Safe/well tolerated 
 Life-saving drug 










Any harm mentioned 
Harm listed in safety advisory: 




 Suicidal thoughts 
 Homicidal thoughts 
 Withdrawal symptoms 
 Lack effect in depression 
 Sexual side effects 
 Side effects (not specified) 
 Stroke/Heart attack 





















 Legal professionals 
 Health professionals 
 Drug regulator 
 Drug industry 
 Medical societies 























a) We report only the most frequently mentioned ones.  
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Table 3. Types of media mentioning the safety concerns described in the advisories 
 Total Coverage Type of news sources* 
Citalopram 19  
Australia 0 - - 
Canada 8 National (n=5) Press service 
Local Urban (n=1) Newspaper 
Local Rural (n=2) Newspaper 
United Kingdom 3 National (n=3) Newspaper 
United States 8 
 
National (n=7) Press service 
Local Urban (n=1) Newspaper 
Denosumab 36   
Australia 4 National (n=4) Blog/websites (n=2) 
Press service (n=1) 
Newspaper (n=1) 
Canada 5 National (n=2) Press service 
Local Urban (n=3) Newspaper 
United Kingdom 1 National (n=1) Newspaper 




Local Urban (n=2) Newspaper 
*Newspapers included both online and print versions. Some press services have a coverage 
that is broader than national but we followed how the databases indexed the geographical 
provenance of the media outlets.  
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Table 4. Disclosure of funding source and investigators’ conflicts of interest in the media 
reports and in the cited scientific articles.  
 Media reports Scientific articles 
Citalopram (n of 
mentions=36) 
(n=21) 
Disclosure of the funding source 
 Pharmaceutical industry funding  
 Public or non-profit funding 
 States that no specific funding was received 
for the study 
8/36 (22.2) 




2/19  (10.5) 
14/19 (73.7) 
3/19 (15.8) 
Disclosure of conflict of interests 
 researchers with ties with pharmaceutical 
industry 








Denosumab (n of 
mentions=31) 
(n=13) 
Disclosure of the funding source 
 Pharmaceutical industry funding 





9/12  (75.0) 
3/12 (25.0) 
Disclosure of conflict of interests 
 researchers with ties with pharmaceutical 
industry 
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Table 5. Characteristics of the media reports on denosumab 
 n (%) 
Media reports 239 (100) 
Brand name in the headline 100 (41.8) 
Treatment indication specified 230 (96.2) 
Any benefit mentioned 
Type of benefitsa  
- Bone metastases 
- Osteoporosis 
- Prevention of breast cancer  
- Medication-induced osteoporosis 
- Giant-cell tumor of the bone 
- Survival rates 
- Tolerability 
-Cost-effectiveness 












Any harm mentioned 














-Side effects (not specified) 
-Lack of effect 
-Diarrhea and/or nausea 









Contraindication 14 (5.9) 





- Drug industry  
- Scientists/academics 



























a) We report only the most frequently mentioned ones.   
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Figure 3. Number of media reports on Citalopram per month  
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Figure 10. Number of media reports on denosumab and dermatologic reactions per month 
 
